港股異動丨復宏漢霖拉昇大漲超15%創階段新高,HLX22治療領域再度拓寬至乳腺癌疾病領域
復宏漢霖(2696.HK)盤中逆勢拉昇大漲超15%報39.2港元,股價創2021年7月以來新高。消息面上,復宏漢霖近日宣佈,公司創新型抗HER2單抗HLX22單抗注射液聯合德曲妥珠單抗治療HER2低表達HR陽性的局部晚期或轉移性乳腺癌的II期臨牀研究(HLX22-BC201)於中國境內完成首例患者給藥。繼HER2陽性胃癌之後,HLX22的治療領域再度拓寬至乳腺癌疾病領域,有望爲更多腫瘤患者帶來新的治療選擇。另外,復星國際4月份多次增持復宏漢霖,據統計,截至目前,復星國際透過復星醫藥持有復宏漢霖已發行股份總數從59.56%增加至63.43%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.